[
  {
    "ts": null,
    "headline": "2 High-Flying Stocks to Target This Week and 1 to Brush Off",
    "summary": "Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expectations are already baked into their prices, leaving little room for error if they stumble even slightly.",
    "url": "https://finnhub.io/api/news?id=cbf0d37aede2b856129a5f9b69b18b14b0f15b23ed18bdb9d4d4820bd4d70f1f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742821371,
      "headline": "2 High-Flying Stocks to Target This Week and 1 to Brush Off",
      "id": 133338231,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TECH",
      "source": "Yahoo",
      "summary": "Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expectations are already baked into their prices, leaving little room for error if they stumble even slightly.",
      "url": "https://finnhub.io/api/news?id=cbf0d37aede2b856129a5f9b69b18b14b0f15b23ed18bdb9d4d4820bd4d70f1f"
    }
  },
  {
    "ts": null,
    "headline": "Bio-Techne to Highlight Advances in the Detection of Clinically Relevant Biomarkers using RNAscope Technologies at the 2025 USCAP Annual Meeting",
    "summary": "Bio-Techne Corporation (NASDAQ: TECH) today announced further advancements in its ongoing strategy to bring translational discoveries to patient care by leveraging RNAscope technology to address unmet needs in biomarker detection and improve pathology laboratory workflows. These advancements will be highlighted in a seminar at the United States and Canadian Academy of Pathology (USCAP) Annual Meeting taking place from March 22-27 in Boston, MA. Advanced Cell Diagnostics (ACD), a Bio-Techne brand",
    "url": "https://finnhub.io/api/news?id=09dcceeb2a61e1c491c8c170b65fc69cdb772a4d9a339199a36a58c8bd0dd7ba",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742814000,
      "headline": "Bio-Techne to Highlight Advances in the Detection of Clinically Relevant Biomarkers using RNAscope Technologies at the 2025 USCAP Annual Meeting",
      "id": 133338232,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TECH",
      "source": "Yahoo",
      "summary": "Bio-Techne Corporation (NASDAQ: TECH) today announced further advancements in its ongoing strategy to bring translational discoveries to patient care by leveraging RNAscope technology to address unmet needs in biomarker detection and improve pathology laboratory workflows. These advancements will be highlighted in a seminar at the United States and Canadian Academy of Pathology (USCAP) Annual Meeting taking place from March 22-27 in Boston, MA. Advanced Cell Diagnostics (ACD), a Bio-Techne brand",
      "url": "https://finnhub.io/api/news?id=09dcceeb2a61e1c491c8c170b65fc69cdb772a4d9a339199a36a58c8bd0dd7ba"
    }
  }
]